1. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention

   • Cosmo Godino
   • Antonio Colombo
   • Alberto Margonato

   Review Article 21 October 2016 Pages: 105 - 120

   

2. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies

   • Rezarta Cuni
   • Iris Parrini
   • Maria Rosa Conte

   Review Article 14 September 2016 Pages: 121 - 134

   

3. Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis

   • Hongxin Cao
   • Lixuan Cui
   • Jiajun Du

   Systematic Review 17 November 2016 Pages: 135 - 153

   

4. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

   • Wei Xu
   • Yang Gong
   • Cuiju Tang

   Original Research Article 24 September 2016 Pages: 155 - 165

   

5. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

   • Hui Liu
   • Rong Fu
   • Zonghong Shao

   Original Research Article 08 October 2016 Pages: 167 - 174

   

6. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study

   • Veronika Tichá
   • Roman Kodým
   • Pavla Kadlecová

   Original Research Article Open access 26 October 2016 Pages: 175 - 186

   

7. Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration

   • Weijun Guo
   • Wenlin Lu
   • Qingyun Zhao

   Original Research Article 26 October 2016 Pages: 187 - 193

8. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

   • Srini Ramanathan
   • Julie A. Di Paolo
   • Brian P. Kearney

   Original Research Article Open access 26 October 2016 Pages: 195 - 205

   

9. Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study

   • Yuri Aleksandrovich Karpov
   • On behalf of the FORTISSIMO physicians

   Original Research Article 22 November 2016 Pages: 207 - 217